Últimas noticias sobre CalciMedica (NASDAQ:CALC) Bolsa

CalciMedica

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

CalciMedica Inc

Calcitech Ltd

Calcol Inc

Stephens &amp; Co. analyst Jeff Garro reiterates Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and maintains $280 price target.

News

Price Target

Reiteration

Analyst Ratings

VEEV

Stephens & Co. Reiterates Overweight on Veeva Systems, Maintains $280 Price Target

Movers

Trading Ideas

ACON

Aclarion Shares Halted n Circuit Breaker

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. analyst Andrew Fein initiated coverage on ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy rating and announced a price target of $8. ImmunityBio shares closed at $3.06 on Wednesday. <a href="https://www.benzinga.com/quote/IBRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jesse Sobelson initiated coverage on Aduro Clean Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUR#NASDAQ">ADUR</a>) with a Buy rating and announced a price target of $50. Aduro Clean Technologies shares closed at $5.09 on Wednesday. <a href="https://www.benzinga.com/quote/ADUR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Laura Chico initiated coverage on Tourmaline Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) with an Outperform rating and announced a price target of $42. Tourmaline Bio shares closed at $12.90 on Wednesday. <a href="https://www.benzinga.com/quote/TRML/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TRML stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06093211/image-20-1024x600.png" alt="" class="wp-image-812304" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06093211/image-20-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06093211/image-20-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06093211/image-20-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06093211/image-20.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Initiation

Markets

ADUR

IBRX

TRML

This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

PMGC Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) ("PMGC" or the "Company") today announced that it will effect a 1-for-7 reverse stock split (the "Split") of its issued and outstanding common stock, par value $0.0001 per share ("Common Stock"), effective at midnight, Eastern time, on March 10, 2025.
Key Details of the Reverse Stock Split:
<ul>
<li>Conversion Ratio: Every 7 shares of issued and outstanding Common Stock will be automatically consolidated into one share, with no further action required from shareholders. &nbsp;</li>
<li>Fractional Shares: Shareholders entitled to fractional shares will receive one full share for each fractional portion. &nbsp;</li>
<li>Updated Stock Identifier: While the trading symbol for the Common Stock will remain "ELAB," the Common Stock will be designated a new CUSIP number (73017P201). &nbsp;</li>
<li>Equity Adjustments: Outstanding stock awards, options, and the shares reserved for the equity incentive plan will be adjusted proportionally to reflect the Split.
<ul>
<li>Warrant Share and Exercise Price Adjustments: Shares of Common Stock underlying outstanding warrants and the exercise price of the outstanding warrants will be adjusted proportionally to reflect this stock split. &nbsp;</li>
</ul>
</li>
</ul>

Stock Split

ELAB

PMGC Holdings Announces 1-For-7 Reverse Stock Split To Maintain Nasdaq Listing Compliance; Effective At Midnight, Eastern Time, On March 10, 2025

General

ENVB

Enveric Biosciences Says On Mar. 4 Regained Nasdaq Compliance

Recent First Quarter 2025 Highlights:
<ul>
<li>Holds over 85 Bitcoin currently;</li>
<li>Reduced debt by over $5.2 million of aggregate principal amount through privately negotiated debt-for-equity exchanges, including approximately $3.7 million of which was completed in 2024;</li>
<li>Improved efficiency of Greenidge's current active fleet miner to 23.8 J/TH as a result of strategic purchases of more efficient miners, from the Company's miner fleet efficiency of 27.1 J/TH as of September 30, 2024;</li>
<li>Proceeding toward a closing on the South Carolina property;</li>
<li>Exploring acquisition of new site in Mississippi, with access to at least 25MW of additional power in Q4 2025;</li>
<li>Added 2.5MW of planned mining capacity at existing Mississippi site;</li>
<li>Exploring subdivision and sale of warehouse at existing Mississippi site;</li>
<li>Provided significant power to the grid in January and February during periods of extreme cold in Northeast;</li>
<li>Continued exploration of accretive business combinations; and</li>
<li>Evaluated future sites with significant low-cost power capacity.</li>
</ul>
Greenidge currently has 119MW of active self-mining, hosting and power generation across sites in New York, Mississippi and North Dakota. With planned mining capacity of 2.5MW expected to be added in Q2 2025 and 25MW by Q4 2025, Greenidge expects to end the year with a total mining capacity of 146.5MW. The Company's active datacenter operations consist of approximately 2.9 EH/s of datacenter hosting and cryptocurrency mining, of which 1.8 E/Hs, is associated with datacenter hosting and 1.1 E/Hs is associated with our cryptocurrency mining.
Greenidge ended the fourth quarter with $8.6 million of cash and $68.5 million in aggregate principal amount of debt.

Guidance

GREE

Greenidge Generation Holdings Shares Recent Q1 Highlights; Holds Over 85 Bitcoin Currently; Reduced Debt By Over $5.2M Of Aggregate Principal Amount Through Privately Negotiated Debt-For-Equity Exchanges

Stephens &amp; Co. analyst Mason Carrico reiterates Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) with a Overweight and maintains $52 price target.

ESTA

Stephens & Co. Reiterates Overweight on Establishment Labs Hldgs, Maintains $52 Price Target

Biotech

OGEN

Oragenics Submits Investigator's Brochure Application For Phase II Clinical Trial Of ONP-002 In Australia

Piper Sandler analyst David Westenberg maintains Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) with a Neutral and lowers the price target from $16 to $12.

ELAN

Piper Sandler Maintains Neutral on Elanco Animal Health, Lowers Price Target to $12

Greenidge Generation Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) reported quarterly sales of $14.80 million which beat the analyst consensus estimate of $13.60 million by 8.82 percent. This is a 24.49 percent decrease over sales of $19.60 million the same period last year.

Earnings

Greenidge Generation Hldg Q4 Sales $14.80M Beat $13.60M Estimate

Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) has outperformed the market over the past 10 years by 1.08% on an annualized basis producing an average annual return of 11.98%. Currently, Workday has a market capitalization of $67.86 billion. 
Buying $1000 In WDAY: If an investor had bought $1000 of WDAY stock 10 years ago, it would be worth $3,139.75 today based on a price of $255.10 for WDAY at the time of writing.
<h3>Workday's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741271414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WDAY

$1000 Invested In Workday 10 Years Ago Would Be Worth This Much Today

Stephens &amp; Co. analyst John Campbell reiterates LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) with a Overweight and maintains $69 price target.

TREE

Stephens & Co. Reiterates Overweight on LendingTree, Maintains $69 Price Target

Barclays analyst Jeff Kessler maintains Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Equal-Weight and lowers the price target from $32 to $26.

Barclays Maintains Equal-Weight on Dine Brands Global, Lowers Price Target to $26

ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) saw its shares rise in the premarket session on Thursday after announcing a major partnership with Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>).
The collaboration will see ECARX provide advanced digital cockpit solutions for vehicles sold under the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44160588/ecarx-to-provide-volkswagen-brazil-and-skoda-with-digital-cockpit-solutions" rel="noreferrer noopener">Volkswagen and Skoda brands globally.</a>
This partnership will involve ECARX supplying a complete digital cockpit solution, which includes both the hardware and software for the ECARX Antora 1000 computing platform and ECARX Cloudpeak software architecture.
The initial phase of this collaboration will focus on launching vehicles in Brazil and India, with plans to expand into additional markets.
The ECARX Antora 1000 is a fourth-generation computing platform powered by a 7nm SE1000 System-on-Chip (SoC) from SiEngine.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44162646/whats-going-on-with-united-microelectronics-stock-today" rel="noreferrer noopener">What&#8217;s Going On With United Microelectronics Stock Today?</a>
The ECARX Cloudpeak software stack, based on Android Automotive OS and Linux, integrates essential services such as Google Maps, Google Assistant, and Google Play, along with mobile integrations like Android Auto and Apple CarPlay.
Ziyu Shen, Chairman and CEO of ECARX, expressed excitement about the opportunity to partner with one of the most respected automakers in the world.
&#8220;This awarding by the Volkswagen Group is a great opportunity for ECARX to partner with one of the most well-known and respected automakers in the world, and also a significant step forward for ECARX as a global company, partnering with international OEMs to deliver the best in intelligent automotive technology,&#8221; Shen added.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, ECX stock has gained over 19% in the past year.
Price Action: ECX shares are trading higher by 20.8% to $2.91 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44138085/donald-trumps-bitcoin-ethereum-xrp-reserve-is-imperfect-but-bullish-says-bitwises-matt-hougan" target="_blank" rel="noreferrer noopener">Donald Trump's Bitcoin, Ethereum, XRP Reserve Is ‘Imperfect' But Bullish, Says Bitwise's Matt Hougan</a></li>
</ul>
Image via Shutterstock.

Equities

Contracts

VWAGY

Why Is ECARX Holdings Stock Gaining Today?

Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) will release its second-quarter financial results, after the <a href="https://www.benzinga.com/quote/COST/earnings">closing bell, on Thursday, March 6.</a>
Analysts expect the company to report quarterly earnings at $4.11 per share, up from $3.92 per share in the year-ago period. Costco projects quarterly revenue of $63.08 billion, compared to $58.44 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Costco has missed analyst revenue estimates in two straight quarters and six of the last 10 quarters overall.
With the recent buzz around Costco, some investors may be eyeing potential gains from the company's dividends too. As of now, Costco offers an annual dividend yield of 0.44%, which is a quarterly dividend amount of $1.16 per share ($4.64 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $1,354,741 or around 1,293 shares. For a more modest $100 per month or $1,200 per year, you would need $271,367 or around 259 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.64 in this case). So, $6,000 / $4.64 = 1,293 ($500 per month), and $1,200 / $4.64 = 259 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
COST Price Action: Shares of Costco gained 1.1% to close at $1,047.75 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Long Ideas

COST

How To Earn $500 A Month From Costco Stock Ahead Of Q2 Earnings

Barclays analyst Christine Cho maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Overweight and lowers the price target from $9 to $8.

ARRY

Barclays Maintains Overweight on Array Technologies, Lowers Price Target to $8

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Michael Yee upgraded ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) from Hold to Buy and raised the price target from $2 to $3. ALX Oncology shares closed at $1.04 on Wednesday. <a href="https://www.benzinga.com/quote/alxo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Kenneth Zener upgraded D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) from Neutral to Buy and announced a $164 price target. D.R. Horton shares closed at $129.37 on Wednesday. <a href="https://www.benzinga.com/quote/dhi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Catharine Trebnick upgraded the rating for Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) from Neutral to Buy and raised the price target from $190 to $235. Zscaler shares closed at $196.45 on Wednesday. <a href="https://www.benzinga.com/quote/zs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Abhi Agarwal upgraded Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Hold to Buy and maintained the price target of $47. Freeport-McMoRan shares closed at $38.16 on Wednesday. <a href="https://www.benzinga.com/quote/fcx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Todd Thomas upgraded CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) from Sector Weight to Overweight and announced a $47 price target. CubeSmart shares closed at $42.46 on Wednesday. <a href="https://www.benzinga.com/quote/cube/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ZS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19-1024x549.png" alt="" class="wp-image-812281" style="width:550px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19.png 1165w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a>

Upgrades

ALXO

CUBE

This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) announced today that it has acquired Alternative Power Generation, Inc. (APG), an electrical engineering and construction management firm, in a stock purchase that closed on March 3. APG adds significant expertise in data center substation design and construction management, microgrids, EV charging stations, and renewable energy projects for the commercial sector. This expertise strengthens Willdan's position in electrical engineering and enhances its capabilities in the energy transition. In 2024, APG generated approximately $37 million in revenue. Transaction terms were not disclosed.

WLDN

Willdan Announces The Acquisition of APG; In 2024, APG Generated ~$37M In Revenue; Transaction Terms Were Not Disclosed

Stephens &amp; Co. analyst Pooran Sharma reiterates Cal-Maine Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) with a Equal-Weight and maintains $97 price target.

CALM

Stephens & Co. Reiterates Equal-Weight on Cal-Maine Foods, Maintains $97 Price Target

Piper Sandler analyst Christopher Raymond maintains ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) with a Overweight and raises the price target from $8 to $9.

Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $9

Offerings

Press Releases

CalciMedica Announces Pricing of Public Offering of Common Stock

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentations at Upcoming Medical Meetings

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

CalciMedica Secures Credit Facility for Up to $32.5 Million

CALC

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

AN2 Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Grace Therapeutics

Hoth Therapeutics

IGC Pharma

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

SCYNEXIS

VYNE Therapeutics

HC Wainwright & Co.

LUCID CAPITAL MARKETS

Oppenheimer

JonesTrading

Comments

CalciMedica

Noticias

Últimas noticias sobre CalciMedica (NASDAQ:CALC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL